Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-19 23:40 | 2025-08-18 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | Officer | OPT+S | $36.24 | 1,883 | $68,232 | 42,065 |
| 2025-08-19 23:09 | 2025-08-15 | ALXO | Alx Oncology Holdings Inc. | Lettmann Jason | Director, Officer | SELL | $0.64 | 2,382 | $1,525 | 212,888 |
| 2025-08-19 23:15 | 2025-08-15 | HRMY | Harmony Biosciences Holdings, Inc. | Kapadia Sandip | Officer | SELL | $36.50 | 21,573 | $787,378 | 0 |
| 2025-08-20 02:40 | 2025-08-18 | DAWN | Day One Biopharmaceuticals, Inc. | York Charles N II | Officer | OPT+S | $6.77 | 4,106 | $27,786 | 278,000 |
| 2025-08-20 03:00 | 2025-08-15 | WVE | Wave Life Sciences Ltd. | Tan Aik Na | Director | OPT+S | $9.25 | 21,000 | $194,250 | 40,388 |
| 2025-08-19 23:06 | 2025-08-18 | MCRB | Seres Therapeutics, Inc. | Young Teresa L. | Officer | OPT+S | $16.65 | 59 | $982 | 5,215 |
| 2025-08-19 23:08 | 2025-08-18 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Director | OPT+S | $16.65 | 217 | $3,613 | 10,609 |
| 2025-08-19 23:07 | 2025-08-18 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | Officer | OPT+S | $16.65 | 73 | $1,215 | 4,548 |
| 2025-08-19 17:41 | 2025-08-18 | PRGO | PERRIGO Co plc | Bezerra Eduardo Guarita | Officer | BUY | $22.74 | 3,000 | $68,207 | 48,949 |
| 2025-08-19 20:45 | 2025-08-15 | CALC | CalciMedica, Inc. | Roberts Eric W | Director, Officer, 10% owner | BUY | $2.90 | 5,076 | $14,709 | 54,399 |
| 2025-08-19 23:05 | 2025-08-15 | ARCT | Arcturus Therapeutics Holdings Inc. | SASSINE ANDY | Director, Officer | BUY | $16.56 | 1,238 | $20,499 | 221,764 |
| 2025-08-19 23:40 | 2025-08-18 | APLS | Apellis Pharmaceuticals Inc. | Watson David O. | Officer | SELL | $27.80 | 5,000 | $139,000 | 123,730 |
| 2025-08-19 17:56 | 2025-08-18 | PRGO | PERRIGO Co plc | Parker Geoffrey M. | Director | BUY | $22.97 | 4,375 | $100,497 | 33,287 |
| 2025-08-19 23:07 | 2025-08-18 | MCRB | Seres Therapeutics, Inc. | DesRosier Thomas | Officer | OPT+S | $16.65 | 76 | $1,265 | 7,455 |
| 2025-08-19 23:27 | 2025-08-18 | KALV | KalVista Pharmaceuticals, Inc. | Yea Christopher | Officer | OPT+S | $13.19 | 2,649 | $34,932 | 129,493 |
| 2025-08-19 23:26 | 2025-08-18 | KALV | KalVista Pharmaceuticals, Inc. | Audhya Paul K. | Officer | OPT+S | $13.19 | 2,939 | $38,757 | 116,533 |
| 2025-08-19 23:26 | 2025-08-18 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $13.19 | 4,409 | $58,141 | 374,548 |
| 2025-08-20 00:10 | 2025-08-15 | COLL | COLLEGIUM PHARMACEUTICAL, INC | SANTINI GINO | Director | OPT+S | $37.19 | 5,405 | $201,018 | 95,042 |
| 2025-08-20 00:28 | 2025-08-18 | ALNY | Alnylam Pharmaceuticals Inc. | Garg Pushkal | Officer | SELL | $455.89 | 2,851 | $1,299,746 | 20,221 |
| 2025-08-20 00:28 | 2025-08-18 | ALNY | Alnylam Pharmaceuticals Inc. | Tanguler Tolga | Officer | SELL | $453.27 | 1,396 | $632,759 | 29,466 |
| 2025-08-20 00:27 | 2025-08-18 | ALNY | Alnylam Pharmaceuticals Inc. | Poulton Jeffrey V. | Officer | SELL | $453.27 | 2,274 | $1,030,727 | 50,121 |
| 2025-08-20 00:27 | 2025-08-18 | ALNY | Alnylam Pharmaceuticals Inc. | Greenstreet Yvonne | Director, Officer | SELL | $453.27 | 6,979 | $3,163,346 | 56,221 |
| 2025-08-20 00:26 | 2025-08-18 | ALNY | Alnylam Pharmaceuticals Inc. | Fitzgerald Kevin Joseph | Officer | SELL | $453.27 | 1,396 | $632,759 | 22,719 |
| 2025-08-20 00:26 | 2025-08-18 | ALNY | Alnylam Pharmaceuticals Inc. | BONNEY MICHAEL W | Director | OPT+S | $450.00 | 11,250 | $5,062,500 | 16,804 |
| 2025-08-20 01:00 | 2025-08-18 | ACAD | Acadia Pharmaceuticals Inc. | Schneyer Mark C. | Officer | SELL | $25.18 | 22,000 | $554,024 | 40,130 |
| 2025-08-19 23:30 | 2025-08-15 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $48.58 | 2,813 | $136,656 | 103,901 |
| 2025-08-19 23:37 | 2025-08-19 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $38.31 | 2,000 | $76,620 | 140,610 |
| 2025-08-19 00:14 | 2025-08-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Officer | SELL | $15.00 | 8,500 | $127,466 | 426,642 |
| 2025-08-19 01:00 | 2025-08-14 | ATAI | Atai Beckley N.V. | Apeiron Investment Group Ltd. | 10% owner | BUY | $2.19 | 8,675,799 | $19,000,000 | 51,045,214 |
| 2025-08-19 01:19 | 2025-08-15 | JNJ | JOHNSON & JOHNSON | Wolk Joseph J | Officer | OPT+S | $176.91 | 16,820 | $2,975,571 | 14,000 |
| 2025-08-18 23:29 | 2025-08-15 | ZLAB | Zai Lab Ltd | Chen Yajing | Officer | OPT+S | $35.42 | 1,438 | $50,932 | 16,720 |
| 2025-08-18 23:28 | 2025-08-15 | EOLS | Evolus, Inc. | Stewart Brady | Director | BUY | $6.82 | 30,000 | $204,486 | 88,629 |
| 2025-08-18 19:00 | 2025-08-14 | CALC | CalciMedica, Inc. | Hebbar Sudarshan | Officer | BUY | $2.74 | 5,976 | $16,362 | 51,976 |
| 2025-08-18 23:33 | 2025-08-15 | EBS | Emergent BioSolutions Inc. | Zoon Kathryn C | Director | SELL | $8.87 | 7,086 | $62,853 | 71,799 |
| 2025-08-18 23:31 | 2025-08-14 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Sensenig Bethany | Director | SELL | $42.25 | 5,369 | $226,840 | 0 |
| 2025-08-18 23:28 | 2025-08-14 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Hudson Frederick M. | Director | SELL | $42.26 | 7,457 | $315,133 | 46,307 |
| 2025-08-19 00:02 | 2025-08-14 | SNDX | Syndax Pharmaceuticals Inc | Podlesak Dennis | Director | OPT+S | $15.19 | 57,600 | $875,100 | 191,763 |
| 2025-08-18 23:35 | 2025-08-14 | RCKT | ROCKET PHARMACEUTICALS, INC. | Schwartz Jonathan David | Officer | SELL | $3.02 | 11,161 | $33,695 | 224,094 |
| 2025-08-18 23:35 | 2025-08-14 | RCKT | ROCKET PHARMACEUTICALS, INC. | Militello John | Officer | SELL | $3.02 | 7,043 | $21,263 | 56,984 |
| 2025-08-18 23:35 | 2025-08-14 | RCKT | ROCKET PHARMACEUTICALS, INC. | Wilson Martin | Officer | SELL | $3.02 | 12,109 | $36,557 | 137,054 |
| 2025-08-19 00:33 | 2025-08-18 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Kelley Shannon T | Officer | SELL | $367.81 | 1,304 | $479,627 | 9,173 |
| 2025-08-18 23:19 | 2025-08-14 | INSM | INSMED Inc | Schaeffer Orlov S Nicole | Officer | SELL | $127.34 | 10,000 | $1,273,363 | 79,764 |
| 2025-08-18 23:29 | 2025-08-15 | ANIP | Ani Pharmaceuticals Inc. | Gassert Chad | Officer | SELL | $86.97 | 20,000 | $1,739,400 | 173,226 |
| 2025-08-18 23:32 | 2025-08-14 | ANIP | Ani Pharmaceuticals Inc. | Shanmugam Muthusamy | Director, Officer | SELL | $88.25 | 100,000 | $8,824,530 | 531,920 |
| 2025-08-19 00:23 | 2025-08-18 | ANIP | Ani Pharmaceuticals Inc. | Leonard Matthew J | Director | SELL | $88.17 | 6,937 | $611,635 | 9,392 |
| 2025-08-18 23:34 | 2025-08-15 | ANIP | Ani Pharmaceuticals Inc. | Walsh Patrick D | Director | SELL | $89.05 | 9,000 | $801,450 | 70,048 |
| 2025-08-15 19:45 | 2025-08-13 | NATR | NATURES SUNSHINE PRODUCTS INC | Lanoy Jonathan David | Officer | SELL | $16.51 | 5,000 | $82,550 | 50,051 |
| 2025-08-16 01:13 | 2025-08-15 | CNTA | Centessa Pharmaceuticals plc | HUSSAIN IQBAL J | Officer | OPT+S | $17.23 | 6,000 | $103,380 | 105,386 |
| 2025-08-16 00:59 | 2025-08-13 | ARWR | Arrowhead Pharmaceuticals Inc. | Hamilton James C | Officer | SELL | $20.00 | 10,000 | $200,000 | 262,122 |
| 2025-08-15 23:13 | 2025-08-15 | LLY | ELI LILLY & Co | Montarce Lucas | Officer | BUY | $691.79 | 715 | $494,627 | 14,685 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.